(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 5.04% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Gilead Sciences's revenue in 2026 is $30,457,000,000.On average, 32 Wall Street analysts forecast GILD's revenue for 2026 to be $38,911,032,719,055, with the lowest GILD revenue forecast at $37,016,381,242,215, and the highest GILD revenue forecast at $40,939,599,352,635. On average, 32 Wall Street analysts forecast GILD's revenue for 2027 to be $41,554,617,109,515, with the lowest GILD revenue forecast at $38,663,041,688,055, and the highest GILD revenue forecast at $44,410,233,831,480.
In 2028, GILD is forecast to generate $43,668,740,648,790 in revenue, with the lowest revenue forecast at $39,068,507,023,740 and the highest revenue forecast at $48,797,195,169,870.